Lewis lung carcinoma

In 1975, Munson discovered that cannabinoids suppress Lewis lung carcinoma cell growth. The mechanism of this action was shown to be inhibition of DNA synthesis[1]Cannabinoids increase the life span of mice carrying Lewis lung tumors and decrease primary tumor size.[2] There are multiple modes of action.[3]

A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass.[4] It is also called 3LL and LLC and is used as a transplantable malignancy.

It has been used in many studies.[5]

References

  1. ^ "In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas.". Cancer Biochem Biophys.. 1977. PMID 616322. 
  2. ^ "Cannabinoids and cancer.". Mini Rev Med Chem.. 2005. doi:10.2174/138955705774329555. PMID 16250836. 
  3. ^ "Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis.". FASEB J. 2003. PMID 12958205. 
  4. ^ Cancer Chemother Rep 2 1972 Nov;(3)1:325
  5. ^ Teicher, Beverly A.; Andrews, Paul A. (2004). Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Press. pp. 197–. ISBN 9781588292285. http://books.google.com/books?id=k4jWvlQ2CCcC&pg=PA197. Retrieved 31 July 2011.